{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:28:03Z","timestamp":1790033283267,"version":"4.0.1"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med. Technol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Vismodegib (VDG), a Smoothened inhibitor approved for basal cell carcinoma, has potential for repurposing in other tumors in which Hedgehog (Hh) signaling contributes to malignancy. However, systemic VDG treatment is associated with relevant adverse effects, and its effective delivery to cutaneous targets remains challenging, supporting the exploration of drug delivery systems for its administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Here, we first screened the response to VDG across four murine tumor cell lines-B16 melanoma, 4T1 mammary carcinoma, Colon-26 colon carcinoma, and LLC1 Lewis lung carcinoma-and then evaluated whether nanocarrier-based delivery could modify its activity in melanoma cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Free VDG produced moderate effects across the screened models, with B16 emerging as the most responsive model showing evidence of growth inhibition together with modulation of Hh-related markers. In this setting, encapsulation of VDG into ultradeformable liposomes (UDL), specially designed for topical application, significantly changed the biological response to treatment, producing a stronger cytotoxic response, concentration-dependent inhibition of cell population expansion, and increased accumulation of dead cells compared with the free drug. An exploratory PAMAM G4.5 dendrimer-based formulation did not show detectable biological effects at the tested concentration, which was constrained by the need to maintain subtoxic dendrimer levels. Although no significant transcriptional changes were detected at the analyzed time point, reduced Gli-1 expression at higher concentrations suggested some degree of Hh pathway modulation by UDL-VDG. However, the enhanced biological effect of UDL-VDG could not be explained solely by canonical Hh inhibition, and responses varied across melanoma models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Overall, these results show that ultradeformable liposomal delivery potentiates the in vitro anti-melanoma activity of VDG and supports its further exploration as a repurposing strategy for candidate non-metastatic cutaneous melanoma. More broadly, these findings support the rationale for topical nanocarrier-based delivery as an approach that could potentially improve local drug availability while helping to reduce some of the limitations associated with systemic administration.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmedt.2026.1826970","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:38Z","timestamp":1780638038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Ultradeformable liposomal delivery of vismodegib modulates its biological activity in melanoma cells"],"prefix":"10.3389","volume":"8","author":[{"given":"Maria Natalia","family":"Calienni","sequence":"first","affiliation":[{"name":"Universidad Nacional de Hurlingham (UNAHUR), Laboratorio de Nanosistemas de Aplicaci\u00f3n Biotecnol\u00f3gica (LANSAB)","place":["Villa Tesei, Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]},{"name":"Comisi\u00f3n de Investigaciones Cient\u00edficas de la Provincia de Buenos Aires (CIC)","place":["La Plata, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Sandoval-Acu\u00f1a","sequence":"additional","affiliation":[{"name":"Departamento de Ciencias B\u00e1sicas, Facultad de Medicina, Universidad de La Frontera","place":["Temuco, Chile"]},{"name":"Laboratory of Tumour Resistance, Institute of Biotechnology, Czech Academy of Sciences","place":["Vestec, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Potomov\u00e1","sequence":"additional","affiliation":[{"name":"Laboratory of Tumour Resistance, Institute of Biotechnology, Czech Academy of Sciences","place":["Vestec, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Emanuel","family":"Ybarra","sequence":"additional","affiliation":[{"name":"Universidad Nacional de Hurlingham (UNAHUR), Laboratorio de Nanosistemas de Aplicaci\u00f3n Biotecnol\u00f3gica (LANSAB)","place":["Villa Tesei, Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]},{"name":"Comisi\u00f3n de Investigaciones Cient\u00edficas de la Provincia de Buenos Aires (CIC)","place":["La Plata, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Truksa","sequence":"additional","affiliation":[{"name":"Laboratory of Tumour Resistance, Institute of Biotechnology, Czech Academy of Sciences","place":["Vestec, Czechia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Montanari","sequence":"additional","affiliation":[{"name":"Universidad Nacional de Hurlingham (UNAHUR), Laboratorio de Nanosistemas de Aplicaci\u00f3n Biotecnol\u00f3gica (LANSAB)","place":["Villa Tesei, Buenos Aires, Argentina"]},{"name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas (CONICET)","place":["Buenos Aires, Argentina"]},{"name":"Comisi\u00f3n de Investigaciones Cient\u00edficas de la Provincia de Buenos Aires (CIC)","place":["La Plata, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2019.05.020","article-title":"New oncologic emergencies: what is there to know about inmunotherapy and its potential side effects?","volume":"66","author":"Barqu\u00edn-Garc\u00eda","year":"2019","journal-title":"Eur J Intern Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1093\/intimm\/dxz012","article-title":"Immunotherapy for skin cancer","volume":"31","author":"Paulson","year":"2019","journal-title":"Int Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ad.2018.09.013","article-title":"Immunotherapy in nonmelanoma skin cancer","volume":"110","author":"Bassas Freixas","year":"2019","journal-title":"Actas Dermosifiliogr"},{"key":"B5","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B6","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.pmbts.2024.03.032","article-title":"Drug repurposing for cancer","volume":"207","author":"Banerjee","year":"2024","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1080\/10717544.2022.2094498","article-title":"Nano-drug co-delivery system of natural active ingredients and chemotherapy drugs for cancer treatment: a review","volume":"29","author":"Li","year":"2022","journal-title":"Drug Deliv"},{"key":"B8","doi-asserted-by":"publisher","first-page":"15330338251338390","DOI":"10.1177\/15330338251338390","article-title":"Drug delivery system for cancer immunotherapy: potential roles, challenge and recent advances","volume":"24","author":"Lin","year":"2025","journal-title":"Technol Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s13346-023-01429-1","article-title":"Cell-nanocarrier drug delivery system: a promising strategy for cancer therapy","volume":"14","author":"Yang","year":"2024","journal-title":"Drug Deliv Transl Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1208\/s12249-024-02765-2","article-title":"Recent trends in nanocarrier-based drug delivery system for prostate cancer","volume":"25","author":"Kumar","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.3390\/cells12162083","article-title":"The role of hedgehog signaling pathway in head and neck squamous cell carcinoma","volume":"12","author":"Cierpikowski","year":"2023","journal-title":"Cells"},{"key":"B12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1055\/s-0040-1709118","article-title":"Current research in melanoma and aggressive nonmelanoma skin cancer","volume":"36","author":"Wilken","year":"2020","journal-title":"Facial Plast Surg"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3210","DOI":"10.3390\/cells11203210","article-title":"Novel approaches in non-melanoma skin cancers-a focus on hedgehog pathway in basal cell carcinoma (BCC)","volume":"11","author":"Chmiel","year":"2022","journal-title":"Cells"},{"key":"B14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s12964-025-02101-6","article-title":"Cooperative hedgehog\/GLI and JAK\/STAT signaling drives immunosuppressive tryptophan\/kynurenine metabolism via synergistic induction of IDO1 in skin cancer","volume":"23","author":"Elmer","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.3390\/ijms24021321","article-title":"Emerging roles of hedgehog signaling in cancer immunity","volume":"24","author":"Giammona","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrd3753","article-title":"Vismodegib","volume":"11","author":"Dlugosz","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-3-319-91442-8_9","article-title":"Vismodegib","volume":"211","author":"Meiss","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1158\/1078-0432.CCR-12-1956","article-title":"U.S. food and drug administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma","volume":"19","author":"Axelson","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ad.2022.01.005","article-title":"Vismodegib and sonidegib in locally advanced and metastatic basal cell carcinoma: update on hedgehog pathway inhibitors","volume":"113","author":"Kurnia Wijaya","year":"2022","journal-title":"Actas Dermosifiliogr"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.7150\/jca.67050","article-title":"Safety and anti-tumor effects of vismodegib in patients with refractory advanced gastric cancer: a single-arm, phase-II trial","volume":"13","author":"Kim","year":"2022","journal-title":"J Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3390\/cells8050394","article-title":"Recent advances in the clinical targeting of hedgehog\/GLI signaling in cancer","volume":"8","author":"Xie","year":"2019","journal-title":"Cells"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/S1470-2045(16)30566-6","article-title":"Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"17","author":"Tang","year":"2016","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3390\/ph15020126","article-title":"Enhancing the bioavailability and efficacy of vismodegib for the control of skin cancer: in vitro and in vivo studies","volume":"15","author":"Salem","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11274","DOI":"10.1039\/D4NR01420K","article-title":"Carriers for hydrophobic drug molecules: lipid-coated hollow mesoporous silica particles, and the influence of shape and size on encapsulation efficiency","volume":"16","author":"Iqbal","year":"2024","journal-title":"Nanoscale"},{"key":"B25","doi-asserted-by":"publisher","first-page":"127581","DOI":"10.1016\/j.molstruc.2019.127581","article-title":"Experimental and theoretical study of the structural features of vismodegib molecule","volume":"1205","author":"Calienni","year":"2020","journal-title":"J Mol Struct"},{"key":"B26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1208\/s12249-025-03210-8","article-title":"An updated perspective on skin disease therapy: from conventional methods to nanocarrier innovations","volume":"26","author":"Shivgotra","year":"2025","journal-title":"AAPS PharmSciTech"},{"key":"B27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/pharmaceutics13020186","article-title":"The topical nanodelivery of vismodegib enhances its skin penetration and performance in vitro while reducing its toxicity in vivo","volume":"13","author":"Calienni","year":"2021","journal-title":"Pharmaceutics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"100186","DOI":"10.1016\/j.onano.2023.100186","article-title":"Enhanced skin delivery of vismodegib-loaded rigid liposomes combined with ethosomes","volume":"14","author":"Fr\u00edas","year":"2023","journal-title":"OpenNano"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101556","DOI":"10.1016\/j.jddst.2020.101556","article-title":"Control of basal cell carcinoma via positively charged ethosomes of vismodegib: in vitro and in vivo studies","volume":"56","author":"Amr Gamal","year":"2020","journal-title":"J Drug Deliv Sci Technol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jconrel.2017.06.022","article-title":"Sonic-hedgehog pathway inhibition normalizes desmoplastic tumor microenvironment to improve chemo- and nanotherapy","volume":"261","author":"Mpekris","year":"2017","journal-title":"J Control Release"},{"key":"B31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ijpharm.2019.05.002","article-title":"Nanoformulation for potential topical delivery of vismodegib in skin cancer treatment","volume":"565","author":"Calienni","year":"2019","journal-title":"Int J Pharm"},{"key":"B32","doi-asserted-by":"publisher","first-page":"100053","DOI":"10.1016\/j.onano.2022.100053","article-title":"Vismodegib in PAMAM-dendrimers for potential theragnosis in skin cancer","volume":"7","author":"Ybarra","year":"2022","journal-title":"OpenNano"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1007\/s11095-011-0455-0","article-title":"Structure-skin permeability relationship of dendrimers","volume":"28","author":"Venuganti","year":"2011","journal-title":"Pharm Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1002\/jps.21603","article-title":"Poly(amidoamine) dendrimers as skin penetration enhancers: influence of charge, generation, and concentration","volume":"98","author":"Venuganti","year":"2009","journal-title":"J Pharm Sci"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1002\/stem.1160","article-title":"HEDGEHOG-GLI signaling drives self-renewal and tumorigenicity of human melanoma-initiating cells","volume":"30","author":"Santini","year":"2012","journal-title":"Stem Cells"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3130","DOI":"10.1158\/1078-0432.CCR-09-2846","article-title":"Targeting hedgehog\u2014a cancer stem cell pathway","volume":"16","author":"Merchant","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4984866","DOI":"10.1155\/2022\/4984866","article-title":"The effects of hedgehog signaling pathway on the proliferation and apoptosis of melanoma cells","volume":"2022","author":"Peng","year":"2022","journal-title":"J Oncol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1158\/0008-5472.CAN-20-1628","article-title":"Targeting mitochondrial iron metabolism suppresses tumor growth and metastasis by inducing mitochondrial dysfunction and mitophagy","volume":"81","author":"Sandoval-Acu\u00f1a","year":"2021","journal-title":"Cancer Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"971905","DOI":"10.3389\/fphar.2022.971905","article-title":"Anticancer regimens containing third generation taxanes SB-T-121605 and SB-T-121606 are highly effective in resistant ovarian carcinoma model","volume":"13","author":"Seborova","year":"2022","journal-title":"Front Pharmacol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41420-025-02327-w","article-title":"Mechanisms and therapeutic potential of the hedgehog signaling pathway in cancer","volume":"11","author":"Cong","year":"2025","journal-title":"Cell Death Discov"},{"key":"B41","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","article-title":"Hedgehog signaling mechanism and role in cancer","volume":"85","author":"Jiang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41392-023-01559-5","article-title":"Hedgehog signaling in tissue homeostasis, cancers and targeted therapies","volume":"8","author":"Jing","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1171418","DOI":"10.3389\/fonc.2023.1171418","article-title":"The emerging roles of hedgehog signaling in tumor immune microenvironment","volume":"13","author":"Wang","year":"2023","journal-title":"Front Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.3390\/cells11162523","article-title":"Canonical hedgehog pathway and noncanonical GLI transcription factor activation in cancer","volume":"11","author":"Suchors","year":"2022","journal-title":"Cells"},{"key":"B45","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3390\/ijms27020762","article-title":"Aberrant activation of the hedgehog pathway in cutaneous melanoma: therapeutic potential of pharmacological inhibitors","volume":"27","author":"Papaccio","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.addr.2003.10.028","article-title":"Lipid vesicles and other colloids as drug carriers on the skin","volume":"56","author":"Cevc","year":"2004","journal-title":"Adv Drug Deliv Rev"},{"key":"B47","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00210-023-02670-8","article-title":"Transfersome, an ultra-deformable lipid-based drug nanocarrier: an updated review with therapeutic applications","volume":"397","author":"Simrah","year":"2024","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"e2300319","DOI":"10.1002\/adhm.202300319","article-title":"A comparison of cellular uptake mechanisms, delivery efficacy, and intracellular fate between liposomes and extracellular vesicles","volume":"12","author":"Gandek","year":"2023","journal-title":"Adv Healthc Mater"},{"key":"B49","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1186\/s11671-018-2728-6","article-title":"Insight into cellular uptake and intracellular trafficking of nanoparticles","volume":"13","author":"Foroozandeh","year":"2018","journal-title":"Nanoscale Res Lett"},{"key":"B50","doi-asserted-by":"publisher","first-page":"106688","DOI":"10.1016\/j.ejps.2023.106688","article-title":"Recent advances and clinical translation of liposomal delivery systems in cancer therapy","volume":"193","author":"Chen","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.3390\/pharmaceutics14102214","article-title":"Liposomes loaded with amaranth unsaponifiable matter and soybean lunasin prevented melanoma tumor development overexpressing caspase-3 in an in vivo model","volume":"14","author":"Casta\u00f1eda-Reyes","year":"2022","journal-title":"Pharmaceutics"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e50051","DOI":"10.7554\/eLife.50051","article-title":"Cholesterol accessibility at the ciliary membrane controls hedgehog signaling","volume":"8","author":"Kinnebrew","year":"2019","journal-title":"eLife"},{"key":"B53","doi-asserted-by":"publisher","first-page":"876815","DOI":"10.3389\/fcell.2022.876815","article-title":"The intimate connection between lipids and hedgehog signaling","volume":"10","author":"Nguyen","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"34160","DOI":"10.1021\/acsomega.3c05425","article-title":"Vismodegib identified as a novel COX-2 inhibitor via deep-learning-based drug repositioning and molecular docking analysis","volume":"8","author":"Yasir","year":"2023","journal-title":"ACS Omega"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3390\/ph6111429","article-title":"Hedgehog pathway blockade inhibits melanoma cell growth in vitro and in vivo","volume":"6","author":"O\u2019Reilly","year":"2013","journal-title":"Pharmaceuticals"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3390\/cancers13092028","article-title":"pH-responsive lipid nanocapsules: a promising strategy for improved resistant melanoma cell internalization","volume":"13","author":"Pautu","year":"2021","journal-title":"Cancers"}],"container-title":["Frontiers in Medical Technology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1826970\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:42:39Z","timestamp":1781181759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmedt.2026.1826970\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":56,"alternative-id":["10.3389\/fmedt.2026.1826970"],"URL":"https:\/\/doi.org\/10.3389\/fmedt.2026.1826970","relation":{},"ISSN":["2673-3129"],"issn-type":[{"value":"2673-3129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1826970"}}